[Usage and costs of treatment with beta interferon among patients with multiple sclerosis in Fars province]
HAKIM Research Journal. 2011; 14 (3): 159-164
en Persa
| IMEMR
| ID: emr-163717
ABSTRACT
Introduction:
Multiple Sclerosis is an inflammatory and demyelinating disease of central nervous system. It is the second most common cause of disability in young adults after trauma. Nowadays, Beta-Interferons are used as the best choice of disease modifying therapy in patients with relapsing-remitting multiple sclerosis. There is a remarkable difference in the uses of these medications between developed and developing countries. The purpose of this study was to evaluate the rate and costs of treatment with Beta-Interferon in patients with MS in Fars Province
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Interferón beta
/
Costo de Enfermedad
Tipo de estudio:
Evaluación Económica en Salud
Límite:
Humanos
Idioma:
Persa
Revista:
HAKIM Res. J.
Año:
2011
Similares
MEDLINE
...
LILACS
LIS